Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company which develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.
| Website: | www.valeant.com |
| Email: | ir@valeant.com |
| Main Phone: | +1 514 744-6792 |
| Address: | 2150 Street Elzéar Boulevard West |
| State: | QC |
| City / Town: | Laval |
| Country: | CAN |
| Postal Code: | H7L 4A8 |
| Exchange: | NDD |
| CEO: | Joseph C. Papa |
| Employees: | 20700 |
| NAICS: | Pharmaceutical Preparation Manufacturing (325412) |
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
The success of companies that prioritize capital allocation, along with pressure from the investment community, has led to a greater emphasis on ROIC among executives.
There are all sorts of ways to make money on the short side.
Dermira ($DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. It is based in Redwood
Stocks rallied in Monday trading following one of Wall Street’s worst weeks of 2013, as investors put on a brave face ahead the possibility that Wednesday will see the Federal Reserve
J.C. Penney Company (JCP) is in a particularly bad place, and has been for some time. At the beginning of 2011 the struggling brick-and-mortar retailer attempted to right the ship and replaced
Upscale department store Neiman Marcus filed a registration statement with the Security and Exchange Commission on Monday for a $100 million initial public offering, more than seven years after
On the heels of Valeant Pharmaceuticals (VRX) agreeing to pay $8.7 billion to buy Bausch & Lomb on Monday, a smaller biotech deal was announced Tuesday morning. British drug maker
On Monday, Warburg Pincus LLC and Valeant Pharmaceuticals International (VRX) agreed on a deal over the sale of the Warburg-owned eye-care company Bausch & Lomb Holdings.Canada’s largest
Markets rebounded dramatically on Wednesday all but ignoring the ongoing Cyprus/E.U. bailout crisis, ahead of a highly anticipated announcement from Federal Reserve Chairman Ben Bernanke regarding
Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company which develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.
| Website: | www.valeant.com |
| Email: | ir@valeant.com |
| Main Phone: | +1 514 744-6792 |
| Address: | 2150 Street Elzéar Boulevard West |
| State: | QC |
| City / Town: | Laval |
| Country: | CAN |
| Postal Code: | H7L 4A8 |
| Exchange: | NDD |
| CEO: | Joseph C. Papa |
| Employees: | 20700 |
| NAICS: | Pharmaceutical Preparation Manufacturing (325412) |
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
The success of companies that prioritize capital allocation, along with pressure from the investment community, has led to a greater emphasis on ROIC among executives.
There are all sorts of ways to make money on the short side.
Dermira ($DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. It is based in Redwood
Stocks rallied in Monday trading following one of Wall Street’s worst weeks of 2013, as investors put on a brave face ahead the possibility that Wednesday will see the Federal Reserve
J.C. Penney Company (JCP) is in a particularly bad place, and has been for some time. At the beginning of 2011 the struggling brick-and-mortar retailer attempted to right the ship and replaced
Upscale department store Neiman Marcus filed a registration statement with the Security and Exchange Commission on Monday for a $100 million initial public offering, more than seven years after
On the heels of Valeant Pharmaceuticals (VRX) agreeing to pay $8.7 billion to buy Bausch & Lomb on Monday, a smaller biotech deal was announced Tuesday morning. British drug maker
On Monday, Warburg Pincus LLC and Valeant Pharmaceuticals International (VRX) agreed on a deal over the sale of the Warburg-owned eye-care company Bausch & Lomb Holdings.Canada’s largest
Markets rebounded dramatically on Wednesday all but ignoring the ongoing Cyprus/E.U. bailout crisis, ahead of a highly anticipated announcement from Federal Reserve Chairman Ben Bernanke regarding
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume 0 | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange NDD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 27 | 63 |
| Number of Buys | 23 | 48 |
| Number of Sells | 4 | 15 |
| Net Activity | 171100 | -532589 |
| Last 10 Buys | Shares |
|---|---|
| Bruno Deschamps | 1,000 |
| Paul S. Herendeen | 1,000 |
| Joseph C. Papa | 1,000 |
| Bruno Deschamps | 1,000 |
| John A. Paulson | 1,000 |
| Bruno Deschamps | 1,000 |
| John A. Paulson | 1,000 |
| Bruno Deschamps | 1,000 |
| Bruno Deschamps | 1,000 |
| Bruno Deschamps | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| John A. Paulson | 1,000 |
| John A. Paulson | 1,000 |
| William A Ackman | 1,000 |
| J. Michael Pearson | 1,000 |
| J. Michael Pearson | 1,000 |
| J. Michael Pearson | 1,000 |
| Jeffrey W. Ubben | 1,000 |
| Jeffrey W. Ubben | 1,000 |
| Jeffrey W. Ubben | 1,000 |
| Jeffrey W. Ubben | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 35 | 35 | 35 | 35 |
| Low Target Price Estimate | 9 | 9 | 9 | 9 |
| Mean Target Price Estimate | 19.83 | 19.67 | 19.67 | 19.83 |
| Standard Deviation | 7.09 | 6.98 | 6.98 | 7.09 |
| Date of Most Recent Estimate | 06/01/18 | 05/22/18 | 05/22/18 | 06/01/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| SD | Specialized Disclosure Report | 7 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| 8-K | Report of unscheduled material events or corporate changes. | 446 | 2018-06-01 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-05-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 6 | 2018-05-10 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-05-08 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-05-08 |
| 4/A | Amendment to a previously filed Form 4 | 1 | 2018-05-08 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 5 | 5 | 5 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 3 | 4 | 4 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 3 | 3 | 3 | 4 |
| Mean Rec. | 2.38 | 2.67 | 2.67 | 2.83 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait